Top

Published in:

01-03-2018 | Clinical Study

Survival outcomes in pediatric recurrent high-grade glioma: results of a 20-year systematic review and meta-analysis

Authors: Cassie Kline, Erin Felton, I. Elaine Allen, Peggy Tahir, Sabine Mueller

Published in: Journal of Neuro-Oncology | Issue 1/2018

Abstract

Recurrent pediatric high-grade glioma is a leading cause of cancer-related death in children. We report results of a systematic review and meta-analysis investigating survival outcome in pediatric patients with recurrent high-grade glioma over the last 20 years. MEDLINE/PubMed, EMBASE, Web of Science and Cochrane Review databases were searched for relevant studies reporting on survival outcomes for pediatric patients with recurrent high-grade glioma treated between 1996 and 2016. Progression-free survival (PFS) and overall survival (OS) were calculated cumulatively over all studies, by therapy subgroup, and by decade of treatment. Random effects models were used to control for heterogeneity as measured by the I² statistic. A total of 17 studies across 4 treatment strategies were included. Eleven investigated traditional chemotherapy, 1 investigated targeted therapy, 3 investigated immunotherapy, and 2 investigated radiotherapy. A total of 129 patients were included with a median age of 10.0 years. Cumulative PFS was 3.5 months (95% CI 2.1–5.0). Cumulative OS was 5.6 months (95% CI 3.9–7.3). OS was 4.0 months (95% CI 1.9–6.1) using traditional chemotherapy, 9.3 months using targeted therapies (95% CI 5.4–13), 6.9 months using immunotherapy (95% CI 2.1–12), and 14 months using reirradiation (95% CI 2.8–25). OS between 1996 and 2006 was 4.2 months (95% CI 2.1–6.2) compared to 8.5 months (95% CI 5.6–11) after 2006. Pediatric patients with recurrent high-grade glioma suffer from poor PFS and OS, regardless of therapy. There may be a trend towards improved OS in the last decade.

Available only for authorised users

Cage TA, Mueller S, Haas-Kogan D, Gupta N (2012) High-grade gliomas in children. Neurosurg Clin N Am 23:515–523. https://doi.org/10.1016/j.nec.2012.04.007 CrossRefPubMed

Broniscer A, Gajjar A (2004) Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. The Oncol 9:197–206

Gottardo NG, Gajjar A (2008) Chemotherapy for malignant brain tumors of childhood. J Child Neurol 23:1149–1159. https://doi.org/10.1177/0883073808321765 CrossRefPubMedPubMedCentral

Braunstein S, Raleigh D, Bindra R, Mueller S, Haas-Kogan D (2017) Pediatric high-grade glioma: current molecular landscape and therapeutic approaches. J Neuro-Oncol. https://doi.org/10.1007/s11060-017-2393-0

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1–e34. https://doi.org/10.1016/j.jclinepi.2009.06.006 CrossRefPubMed

Mahoney DH Jr, Strother D, Camitta B, Bowen T, Ghim T, Pick T, Wall D, Yu L, Shuster JJ, Friedman H (1996) High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric oncology group study. J Clin Oncol 14:382–388. https://doi.org/10.1200/JCO.1996.14.2.382 CrossRefPubMed

Chamberlain MC (1997) Recurrent supratentorial malignant gliomas in children. Long-term salvage therapy with oral etoposide. Arch Neurol 54:554–558CrossRefPubMed

Wagner S, Erdlenbruch B, Langler A, Gnekow A, Kuhl J, Albani M, Volpel S, Bucsky P, Emser A, Peters O, Wolff JE (2004) Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology. Cancer 100:1750–1757. https://doi.org/10.1002/cncr.20168 CrossRefPubMed

Shih CS, Hale GA, Gronewold L, Tong X, Laningham FH, Gilger EA, Srivastava DK, Kun LE, Gajjar A, Fouladi M (2008) High-dose chemotherapy with autologous stem cell rescue for children with recurrent malignant brain tumors. Cancer 112:1345–1353. https://doi.org/10.1002/cncr.23305 CrossRefPubMed

10.

Saurez G, Cabanas R, Zaldivar M, Garnier T, Iglesias B, Piedra P, Castillo MR, Longchong M, Iznaga N, Lage A (2009) Clinical experience with nimotuzumab in cuban pediatric patients with brain tumors, 2005 to 2007. MEDICC Rev 11:27–33PubMed

11.

Parekh C, Jubran R, Erdreich-Epstein A, Panigrahy A, Bluml S, Finlay J, Dhall G (2011) Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen. J Neuro-Oncol 103:673–680. https://doi.org/10.1007/s11060-010-0444-x CrossRef

12.

Lasky JL 3rd, Panosyan EH, Plant A, Davidson T, Yong WH, Prins RM, Liau LM, Moore TB (2013) Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. Anticancer Res 33:2047–2056PubMedPubMedCentral

13.

Muller K, Scheithauer H, Pietschmann S, Hoffmann M, Rossler J, Graf N, Baumert BG, Christiansen H, Kortmann RD, Kramm CM, von Bueren AO (2014) Reirradiation as part of a salvage treatment approach for progressive non-pontine pediatric high-grade gliomas: preliminary experiences from the German HIT-HGG study group. Radiat Oncol 9:177. https://doi.org/10.1186/1748-717X-9-177 CrossRefPubMedPubMedCentral

14.

Ardon H, De Vleeschouwer S, Van Calenbergh F, Claes L, Kramm CM, Rutkowski S, Wolff JEA, Van Gool SW (2010) Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediatr Blood Cancer 54:519–525. https://doi.org/10.1002/pbc.22319 PubMed

15.

Bouffet E, Khelfaoui F, Philip I, Biron P, Brunat-Mentigny M, Philip T (1997) High-dose carmustine for high-grade gliomas in childhood. Cancer Chemother Pharmacol 39:376–379. https://doi.org/10.1007/s002800050586 CrossRefPubMed

16.

Bouffet E, Mottolese C, Jouvet A, Philip I, Frappaz D, Carrie C, Brunat-Mentigny M (1997) Etoposide and thiotepa followed by ABMT (autologous bone marrow transplantation) in children and young adults with high-grade gliomas. Eur J Cancer 33:91–95CrossRefPubMed

17.

De Sio L, Milano GM, Castellano A, Jenkner A, Fidani P, Dominici C, Donfrancesco A (2006) Temozolomide in resistant or relapsed pediatric solid tumors. Pediatr Blood Cancer 47:30–36. https://doi.org/10.1002/pbc.20516 CrossRefPubMed

18.

Gilheeney SW, Khakoo Y, Souweidane M, Wolden S, Boulad F, Dunkel IJ (2010) Thiotepa/topotecan/carboplatin with autologous stem cell rescue in recurrent/refractory/poor prognosis pediatric malignancies of the central nervous system. Pediatr Blood Cancer 54:591–595. https://doi.org/10.1002/pbc.22347 PubMed

19.

Gilman AL, Jacobsen C, Bunin N, Levine J, Goldman F, Bendel A, Joyce M, Anderson P, Rozans M, Wall DA, Macdonald TJ, Simon S, Kadota RP (2011) Phase I study of tandem high-dose chemotherapy with autologous peripheral blood stem cell rescue for children with recurrent brain tumors: a pediatric blood and marrow transplant consortium study. Pediatr Blood Cancer 57:506–513. https://doi.org/10.1002/pbc.22899 CrossRefPubMed

20.

Iwami K, Shimato S, Ohno M, Okada H, Nakahara N, Sato Y, Yoshida J, Suzuki S, Nishikawa H, Shiku H, Natsume A, Wakabayashi T (2012) Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor alpha2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele. Cytotherapy 14:733–742. https://doi.org/10.3109/14653249.2012.666633 CrossRefPubMed

21.

Lashford LS, Thiesse P, Jouvet A, Jaspan T, Couanet D, Griffiths PD, Doz F, Ironside J, Robson K, Hobson R, Dugan M, Pearson ADJ, Vassal G, Frappaz D (2002) Temozolomide in malignant gliomas of childhood: a United Kingdom Children’s Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol 20:4684–4691. https://doi.org/10.1200/JCO.2002.08.141 CrossRefPubMed

22.

Papadakis V, Dunkel IJ, Cramer LD, Kramer E, Papadopoulos E, Goldman S, Packer RJ, Willoughby M, Baker D, Garvin J, Strandjord S, Coccia P, Kaplan AM, Klemperer M, Finlay JL (2000) High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumors. Bone Marrow Transplant 26:153–160CrossRefPubMed

23.

Verschuur AC, Grill J, Lelouch-Tubiana A, Couanet D, Kalifa C, Vassal G (2004) Temozolomide in paediatric high-grade glioma: a key for combination therapy? Br J cancer 91:425–429. https://doi.org/10.1038/sj.bjc.6601997 CrossRefPubMedPubMedCentral

24.

Jakacki RI, Cohen KJ, Buxton A, Krailo MD, Burger PC, Rosenblum MK, Brat DJ, Hamilton RL, Eckel SP, Zhou T, Lavey RS, Pollack IF (2016) Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children’s Oncology Group ACNS0423 study. Neuro Oncol 18:1442–1450. https://doi.org/10.1093/neuonc/now038 CrossRefPubMedPubMedCentral

25.

Wolff JE, Wagner S, Reinert C, Gnekow A, Kortmann RD, Kuhl J, Van Gool SW (2006) Maintenance treatment with interferon-gamma and low-dose cyclophosphamide for pediatric high-grade glioma. J Neuro-Oncol 79:315–321. https://doi.org/10.1007/s11060-006-9147-8 CrossRef

26.

Wolff JE, Driever PH, Erdlenbruch B, Kortmann RD, Rutkowski S, Pietsch T, Parker C, Metz MW, Gnekow A, Kramm CM (2010) Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol. Cancer 116:705–712. https://doi.org/10.1002/cncr.24730 CrossRefPubMed

27.

Janssens GO, Gandola L, Bolle S, Mandeville H, Ramos-Albiac M, van Beek K, Benghiat H, Hoeben B, Morales La Madrid A, Kortmann RD, Hargrave D, Menten J, Pecori E, Biassoni V, von Bueren AO, van Vuurden DG, Massimino M, Sturm D, Peters M, Kramm CM (2017) Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: a matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. Eur J Cancer 73:38–47. https://doi.org/10.1016/j.ejca.2016.12.007 CrossRefPubMed

28.

Paganelli G, Grana C, Chinol M, Cremonesi M, De Cicco C, De Braud F, Robertson C, Zurrida S, Casadio C, Zoboli S, Siccardi AG, Veronesi U (1999) Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 26:348–357CrossRefPubMed

Title: Survival outcomes in pediatric recurrent high-grade glioma: results of a 20-year systematic review and meta-analysis
Authors: Cassie Kline
Erin Felton
I. Elaine Allen
Peggy Tahir
Sabine Mueller
Publication date: 01-03-2018
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2018
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-017-2701-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Survival outcomes in pediatric recurrent high-grade glioma: results of a 20-year systematic review and meta-analysis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2018

Double somatic SMARCB1 and NF2 mutations in sporadic spinal schwannoma

External validity of two nomograms for predicting distant brain failure after radiosurgery for brain metastases in a bi-institutional independent patient cohort

Outcome of children and adolescents with central nervous system tumors in phase I trials

Melanoma brain metastases harboring BRAF V600K or NRAS mutations are associated with an increased local failure rate following conventional therapy

Stereotactic radiosurgery for central nervous system hemangioblastoma: systematic review and meta-analysis

Pre-operative language ability in patients with presumed low-grade glioma